atc_level_01_code,atc_level_01_name,atc_level_02_code,atc_level_02_name,atc_level_03_code,atc_level_03_name,atc_level_04_code,atc_level_04_name,atc_level_04_note,atc_level_05_code,atc_level_05_name,atc_level_05_note,DDD_N,DDD_O,DDD_P,DDD_R,DDD_sc_implant,DDD_SL,DDD_TD,DDD_urethral,DDD_V,unit_N,unit_O,unit_P,unit_R,unit_sc_implant,unit_SL,unit_TD,unit_urethral,unit_V
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AA,Antibiotics,The DDDs are based on the treatment of vaginal infections.,G01AA01,nystatin,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,MU
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AA,Antibiotics,The DDDs are based on the treatment of vaginal infections.,G01AA02,natamycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,NA,NA,NA,NA,NA,NA,NA,NA,mg
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AA,Antibiotics,The DDDs are based on the treatment of vaginal infections.,G01AA03,amphotericin B,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,g
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AA,Antibiotics,The DDDs are based on the treatment of vaginal infections.,G01AA04,candicidin,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,NA,NA,NA,NA,NA,NA,NA,NA,mg
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AA,Antibiotics,The DDDs are based on the treatment of vaginal infections.,G01AA05,chloramphenicol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AA,Antibiotics,The DDDs are based on the treatment of vaginal infections.,G01AA06,hachimycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AA,Antibiotics,The DDDs are based on the treatment of vaginal infections.,G01AA07,oxytetracycline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AA,Antibiotics,The DDDs are based on the treatment of vaginal infections.,G01AA08,carfecillin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AA,Antibiotics,The DDDs are based on the treatment of vaginal infections.,G01AA09,mepartricin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AA,Antibiotics,The DDDs are based on the treatment of vaginal infections.,G01AA10,clindamycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,g
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AA,Antibiotics,The DDDs are based on the treatment of vaginal infections.,G01AA11,pentamycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AA,Antibiotics,The DDDs are based on the treatment of vaginal infections.,G01AA51,"nystatin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AB,Arsenic compounds,The DDDs are based on the treatment of vaginal infections.,G01AB01,acetarsol,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.5,NA,NA,NA,NA,NA,NA,NA,NA,g
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AC,Quinoline derivatives,The DDDs are based on the treatment of vaginal infections.,G01AC01,diiodohydroxyquinoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,g
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AC,Quinoline derivatives,The DDDs are based on the treatment of vaginal infections.,G01AC02,clioquinol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AC,Quinoline derivatives,The DDDs are based on the treatment of vaginal infections.,G01AC03,chlorquinaldol,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,g
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AC,Quinoline derivatives,The DDDs are based on the treatment of vaginal infections.,G01AC05,dequalinium,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,NA,NA,NA,NA,NA,NA,NA,NA,mg
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AC,Quinoline derivatives,The DDDs are based on the treatment of vaginal infections.,G01AC06,broxyquinoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,g
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AC,Quinoline derivatives,The DDDs are based on the treatment of vaginal infections.,G01AC30,oxyquinoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AD,Organic acids,The DDDs are based on the treatment of vaginal infections.,G01AD01,lactic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AD,Organic acids,The DDDs are based on the treatment of vaginal infections.,G01AD02,acetic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AD,Organic acids,The DDDs are based on the treatment of vaginal infections.,G01AD03,ascorbic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.25,NA,NA,NA,NA,NA,NA,NA,NA,g
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AE,Sulfonamides,The DDDs are based on the treatment of vaginal infections.,G01AE01,sulfatolamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AE,Sulfonamides,The DDDs are based on the treatment of vaginal infections.,G01AE10,combinations of sulfonamides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF01,metronidazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.5,NA,NA,NA,NA,NA,NA,NA,NA,g
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF02,clotrimazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,g
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF04,miconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,g
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF05,econazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,g
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF06,ornidazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF07,isoconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.6,NA,NA,NA,NA,NA,NA,NA,NA,g
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF08,tioconazole,Single dose treatment,NA,NA,NA,NA,NA,NA,NA,NA,0.3,NA,NA,NA,NA,NA,NA,NA,NA,g
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF11,ketoconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.4,NA,NA,NA,NA,NA,NA,NA,NA,g
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF12,fenticonazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,g
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF13,azanidazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF14,propenidazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF15,butoconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,g
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF16,omoconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF17,oxiconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF18,flutrimazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF19,sertaconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF20,combinations of imidazole derivatives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF21,tinidazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,g
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF55,"econazole, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AG,Triazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AG02,terconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,80,NA,NA,NA,NA,NA,NA,NA,NA,mg
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX01,clodantoin,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,g
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX02,inosine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX03,policresulen,NA,NA,NA,NA,NA,NA,NA,NA,NA,90,NA,NA,NA,NA,NA,NA,NA,NA,mg
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX05,nifuratel,NA,NA,0.6,NA,NA,NA,NA,NA,NA,0.6,NA,g,NA,NA,NA,NA,NA,NA,g
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX06,furazolidone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX09,methylrosaniline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX11,povidone-iodine,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,g
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX12,ciclopirox,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX13,protiofate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX14,lactobacillus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX15,copper usnate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX16,hexetidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX17,dapivirine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX66,"octenidine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01B,ANTIINFECTIVES/ANTISEPTICS IN COMBINATION WITH CORTICOSTEROIDS,G01BA,Antibiotics and corticosteroids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01B,ANTIINFECTIVES/ANTISEPTICS IN COMBINATION WITH CORTICOSTEROIDS,G01BC,Quinoline derivatives and corticosteroids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01B,ANTIINFECTIVES/ANTISEPTICS IN COMBINATION WITH CORTICOSTEROIDS,G01BD,Antiseptics and corticosteroids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01B,ANTIINFECTIVES/ANTISEPTICS IN COMBINATION WITH CORTICOSTEROIDS,G01BE,Sulfonamides and corticosteroids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01B,ANTIINFECTIVES/ANTISEPTICS IN COMBINATION WITH CORTICOSTEROIDS,G01BF,Imidazole derivatives and corticosteroids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02A,UTEROTONICS,G02AB,Ergot alkaloids,The DDDs are based on use in delivery.,G02AB01,methylergometrine,NA,NA,0.2,0.2,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02A,UTEROTONICS,G02AB,Ergot alkaloids,The DDDs are based on use in delivery.,G02AB02,ergot alkaloids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02A,UTEROTONICS,G02AB,Ergot alkaloids,The DDDs are based on use in delivery.,G02AB03,ergometrine,NA,NA,0.2,0.2,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02A,UTEROTONICS,G02AC,"Ergot alkaloids and oxytocin incl. analogues, in combination",NA,G02AC01,methylergometrine and oxytocin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02A,UTEROTONICS,G02AD,Prostaglandins,NA,G02AD01,dinoprost,NA,NA,NA,25,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02A,UTEROTONICS,G02AD,Prostaglandins,NA,G02AD02,dinoprostone,NA,NA,0.5,NA,NA,NA,NA,NA,NA,0.5,NA,mg,NA,NA,NA,NA,NA,NA,mg
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02A,UTEROTONICS,G02AD,Prostaglandins,NA,G02AD03,gemeprost,Single dose treatment,NA,NA,NA,NA,NA,NA,NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,mg
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02A,UTEROTONICS,G02AD,Prostaglandins,NA,G02AD04,carboprost,Single dose treatment,NA,NA,2.5,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02A,UTEROTONICS,G02AD,Prostaglandins,NA,G02AD05,sulprostone,NA,NA,NA,0.5,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02A,UTEROTONICS,G02AD,Prostaglandins,NA,G02AD06,misoprostol,"vaginal insert, refers to the content of one vaginal insert",NA,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,mg
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02A,UTEROTONICS,G02AD,Prostaglandins,NA,G02AD06,misoprostol,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02A,UTEROTONICS,G02AX,Other uterotonics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02B,CONTRACEPTIVES FOR TOPICAL USE,G02BA,Intrauterine contraceptives,NA,G02BA01,plastic IUD,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02B,CONTRACEPTIVES FOR TOPICAL USE,G02BA,Intrauterine contraceptives,NA,G02BA02,plastic IUD with copper,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02B,CONTRACEPTIVES FOR TOPICAL USE,G02BA,Intrauterine contraceptives,NA,G02BA03,plastic IUD with progestogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02B,CONTRACEPTIVES FOR TOPICAL USE,G02BB,Intravaginal contraceptives,The DDDs for combined devices containing estrogen and progestogen are based on use in menstrual cycles of 28 days.  Thus the DDD is 0.0357 UD (1 UD = 1 device).,G02BB01,vaginal ring with progestogen and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02B,CONTRACEPTIVES FOR TOPICAL USE,G02BB,Intravaginal contraceptives,The DDDs for combined devices containing estrogen and progestogen are based on use in menstrual cycles of 28 days.  Thus the DDD is 0.0357 UD (1 UD = 1 device).,G02BB02,vaginal ring with progestogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CA,"Sympathomimetics, labour repressants",The DDDs are based on use as labour repressants.,G02CA01,ritodrine,NA,NA,40,40,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CA,"Sympathomimetics, labour repressants",The DDDs are based on use as labour repressants.,G02CA02,buphenine,NA,NA,NA,30,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CA,"Sympathomimetics, labour repressants",The DDDs are based on use as labour repressants.,G02CA03,fenoterol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CB,Prolactine inhibitors,"The DDDs are based on use as lactation inhibitors.  The DDD for parenteral depot formulations of bromocriptine is equal to the DDD for oral administration, based on the assumption that the single dose parenteral treatment equals 14 days of oral treatment.",G02CB01,bromocriptine,NA,NA,5,5,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CB,Prolactine inhibitors,"The DDDs are based on use as lactation inhibitors.  The DDD for parenteral depot formulations of bromocriptine is equal to the DDD for oral administration, based on the assumption that the single dose parenteral treatment equals 14 days of oral treatment.",G02CB02,lisuride,NA,NA,0.6,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CB,Prolactine inhibitors,"The DDDs are based on use as lactation inhibitors.  The DDD for parenteral depot formulations of bromocriptine is equal to the DDD for oral administration, based on the assumption that the single dose parenteral treatment equals 14 days of oral treatment.",G02CB03,cabergoline,NA,NA,0.5,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CB,Prolactine inhibitors,"The DDDs are based on use as lactation inhibitors.  The DDD for parenteral depot formulations of bromocriptine is equal to the DDD for oral administration, based on the assumption that the single dose parenteral treatment equals 14 days of oral treatment.",G02CB04,quinagolide,NA,NA,75,NA,NA,NA,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CB,Prolactine inhibitors,"The DDDs are based on use as lactation inhibitors.  The DDD for parenteral depot formulations of bromocriptine is equal to the DDD for oral administration, based on the assumption that the single dose parenteral treatment equals 14 days of oral treatment.",G02CB05,metergoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CB,Prolactine inhibitors,"The DDDs are based on use as lactation inhibitors.  The DDD for parenteral depot formulations of bromocriptine is equal to the DDD for oral administration, based on the assumption that the single dose parenteral treatment equals 14 days of oral treatment.",G02CB06,terguride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CC,Antiinflammatory products for vaginal administration,NA,G02CC01,ibuprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CC,Antiinflammatory products for vaginal administration,NA,G02CC02,naproxen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CC,Antiinflammatory products for vaginal administration,NA,G02CC03,benzydamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CC,Antiinflammatory products for vaginal administration,NA,G02CC04,flunoxaprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CX,Other gynecologicals,NA,G02CX01,atosiban,NA,NA,NA,165,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CX,Other gynecologicals,NA,G02CX02,flibanserin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CX,Other gynecologicals,NA,G02CX03,Agni casti fructus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CX,Other gynecologicals,NA,G02CX04,Cimicifugae rhizoma,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CX,Other gynecologicals,NA,G02CX05,bremelanotide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CX,Other gynecologicals,NA,G02CX06,fezolinetant,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA01,etynodiol and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA02,quingestanol and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA03,lynestrenol and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA04,megestrol and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA05,norethisterone and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA06,norgestrel and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA07,levonorgestrel and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA08,medroxyprogesterone and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA09,desogestrel and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA10,gestodene and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA11,norgestimate and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA12,drospirenone and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA13,norelgestromin and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA14,nomegestrol and estradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA15,chlormadinone and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA16,dienogest and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA17,medroxyprogesterone and estradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA18,drospirenone and estetrol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AB01,megestrol and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AB02,lynestrenol and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AB03,levonorgestrel and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AB04,norethisterone and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AB05,desogestrel and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AB06,gestodene and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AB07,chlormadinone and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AB08,dienogest and estradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AB09,norgestimate and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AC,Progestogens,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AC01,norethisterone,NA,NA,NA,2.5,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AC,Progestogens,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AC02,lynestrenol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AC,Progestogens,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AC03,levonorgestrel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AC,Progestogens,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AC04,quingestanol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AC,Progestogens,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AC05,megestrol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AC,Progestogens,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AC06,medroxyprogesterone,NA,NA,NA,1.67,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AC,Progestogens,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AC07,norgestrienone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AC,Progestogens,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AC08,etonogestrel,NA,NA,NA,NA,NA,68,NA,NA,NA,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AC,Progestogens,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AC09,desogestrel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AC,Progestogens,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AC10,drospirenone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AD,Emergency contraceptives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AD01,levonorgestrel,NA,NA,1.5,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AD,Emergency contraceptives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AD02,ulipristal,NA,NA,30,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03B,ANDROGENS,G03BA,3-oxoandrosten (4) derivatives,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use in substitution therapy in male hypogonadism.  The DDDs for patches (e.g. testosterone) are given in amount delivered. The DDD for parenteral and oral testosterone is expressed as declared amount of ester. The DDD for TD and SL route of administration is expressed as declared amount of testosterone.,G03BA01,fluoxymesterone,NA,NA,5,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03B,ANDROGENS,G03BA,3-oxoandrosten (4) derivatives,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use in substitution therapy in male hypogonadism.  The DDDs for patches (e.g. testosterone) are given in amount delivered. The DDD for parenteral and oral testosterone is expressed as declared amount of ester. The DDD for TD and SL route of administration is expressed as declared amount of testosterone.,G03BA02,methyltestosterone,NA,NA,25,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03B,ANDROGENS,G03BA,3-oxoandrosten (4) derivatives,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use in substitution therapy in male hypogonadism.  The DDDs for patches (e.g. testosterone) are given in amount delivered. The DDD for parenteral and oral testosterone is expressed as declared amount of ester. The DDD for TD and SL route of administration is expressed as declared amount of testosterone.,G03BA03,testosterone,gel,NA,NA,NA,NA,NA,NA,50,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03B,ANDROGENS,G03BA,3-oxoandrosten (4) derivatives,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use in substitution therapy in male hypogonadism.  The DDDs for patches (e.g. testosterone) are given in amount delivered. The DDD for parenteral and oral testosterone is expressed as declared amount of ester. The DDD for TD and SL route of administration is expressed as declared amount of testosterone.,G03BA03,testosterone,NA,NA,0.12,18,0.12,NA,60,3,NA,NA,NA,g,mg,g,NA,mg,mg,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03B,ANDROGENS,G03BB,5-androstanon (3) derivatives,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use in substitution therapy in male hypogonadism.  The DDDs for patches (e.g. testosterone) are given in amount delivered.,G03BB01,mesterolone,NA,NA,50,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03B,ANDROGENS,G03BB,5-androstanon (3) derivatives,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use in substitution therapy in male hypogonadism.  The DDDs for patches (e.g. testosterone) are given in amount delivered.,G03BB02,androstanolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA01,ethinylestradiol,NA,NA,25,NA,NA,NA,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA03,estradiol,depot long duration,NA,NA,0.3,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA03,estradiol,depot short duration,NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA03,estradiol,gel,NA,NA,NA,NA,NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA03,estradiol,"patch, refer to amount delivered per 24 hours",NA,NA,NA,NA,NA,NA,50,NA,NA,NA,NA,NA,NA,NA,NA,mcg,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA03,estradiol,spray,NA,NA,NA,NA,NA,NA,1.53,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA03,estradiol,"vaginal ring,  refers to amount delivered per 24 hours",NA,NA,NA,NA,NA,NA,NA,NA,7.5,NA,NA,NA,NA,NA,NA,NA,NA,mcg
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA03,estradiol,NA,0.3,2,NA,5,NA,NA,NA,NA,25,mg,mg,NA,mg,NA,NA,NA,NA,mcg
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA04,estriol,NA,NA,2,2,NA,NA,NA,NA,NA,0.2,NA,mg,mg,NA,NA,NA,NA,NA,mg
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA06,chlorotrianisene,NA,NA,24,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA07,estrone,NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA09,promestriene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA53,"estradiol, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA57,conjugated estrogens,NA,NA,0.625,NA,NA,NA,NA,NA,NA,0.625,NA,mg,NA,NA,NA,NA,NA,NA,mg
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CB,"Synthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used.",G03CB01,dienestrol,NA,NA,2.5,NA,NA,NA,NA,NA,NA,0.2,NA,mg,NA,NA,NA,NA,NA,NA,mg
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CB,"Synthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used.",G03CB02,diethylstilbestrol,NA,NA,0.2,NA,NA,NA,NA,NA,NA,1,NA,mg,NA,NA,NA,NA,NA,NA,mg
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CB,"Synthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used.",G03CB03,methallenestril,NA,NA,9,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CB,"Synthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used.",G03CB04,moxestrol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CC,"Estrogens, combinations with other drugs","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used.",G03CC02,dienestrol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CC,"Estrogens, combinations with other drugs","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used.",G03CC03,methallenestril,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CC,"Estrogens, combinations with other drugs","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used.",G03CC04,estrone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CC,"Estrogens, combinations with other drugs","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used.",G03CC05,diethylstilbestrol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CC,"Estrogens, combinations with other drugs","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used.",G03CC06,estriol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CC,"Estrogens, combinations with other drugs","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used.",G03CC07,conjugated estrogens and bazedoxifene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CX,Other estrogens,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used.",G03CX01,tibolone,NA,NA,2.5,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DA,Pregnen (4) derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DA01,gestonorone,NA,NA,NA,30,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DA,Pregnen (4) derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DA02,medroxyprogesterone,NA,NA,5,7,NA,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DA,Pregnen (4) derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DA03,hydroxyprogesterone,NA,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DA,Pregnen (4) derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DA04,progesterone,NA,NA,0.3,5,0.2,NA,NA,NA,NA,90,NA,g,mg,g,NA,NA,NA,NA,mg
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DB,Pregnadien derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DB01,dydrogesterone,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DB,Pregnadien derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DB02,megestrol,NA,NA,5,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DB,Pregnadien derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DB03,medrogestone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DB,Pregnadien derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DB04,nomegestrol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DB,Pregnadien derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DB05,demegestone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DB,Pregnadien derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DB06,chlormadinone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DB,Pregnadien derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DB07,promegestone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DB,Pregnadien derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DB08,dienogest,NA,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DC,Estren derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DC01,allylestrenol,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DC,Estren derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DC02,norethisterone,NA,NA,5,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DC,Estren derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DC03,lynestrenol,NA,NA,5,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DC,Estren derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DC04,ethisterone,NA,NA,5,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DC,Estren derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DC06,etynodiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DC,Estren derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DC31,methylestrenolone,NA,NA,5,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03E,ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION,G03EA,Androgens and estrogens,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the treatment of climacterical ailments.,G03EA01,methyltestosterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03E,ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION,G03EA,Androgens and estrogens,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the treatment of climacterical ailments.,G03EA02,testosterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03E,ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION,G03EA,Androgens and estrogens,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the treatment of climacterical ailments.,G03EA03,prasterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03E,ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION,G03EB,"Androgen, progestogen and estrogen in combination",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03E,ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION,G03EK,Androgens and female sex hormones in combination with other drugs,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the treatment of climacterical ailments.,G03EK01,methyltestosterone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA01,norethisterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA02,hydroxyprogesterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA03,ethisterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA04,progesterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA05,methylnortestosterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA06,etynodiol and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA07,lynestrenol and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA08,megestrol and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA09,noretynodrel and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA10,norgestrel and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA11,levonorgestrel and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA12,medroxyprogesterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA13,norgestimate and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA14,dydrogesterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA15,dienogest and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA16,trimegestone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA17,drospirenone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FB01,norgestrel and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FB02,lynestrenol and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FB03,chlormadinone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FB04,megestrol and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FB05,norethisterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FB06,medroxyprogesterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FB07,medrogestone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FB08,dydrogesterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FB09,levonorgestrel and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FB10,desogestrel and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FB11,trimegestone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FB12,nomegestrol and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GA,Gonadotropins,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GA01,chorionic gonadotrophin,NA,NA,NA,250,NA,NA,NA,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GA,Gonadotropins,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GA02,human menopausal gonadotrophin,NA,NA,NA,75,NA,NA,NA,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GA,Gonadotropins,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GA03,serum gonadotrophin,NA,NA,NA,750,NA,NA,NA,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GA,Gonadotropins,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GA04,urofollitropin,NA,NA,NA,75,NA,NA,NA,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GA,Gonadotropins,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GA05,follitropin alfa,NA,NA,NA,75,NA,NA,NA,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GA,Gonadotropins,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GA06,follitropin beta,NA,NA,NA,75,NA,NA,NA,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GA,Gonadotropins,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GA07,lutropin alfa,NA,NA,NA,75,NA,NA,NA,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GA,Gonadotropins,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GA08,choriogonadotropin alfa,NA,NA,NA,0.25,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GA,Gonadotropins,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GA09,corifollitropin alfa,NA,NA,NA,0.15,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GA,Gonadotropins,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GA10,follitropin delta,NA,NA,NA,12,NA,NA,NA,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GA,Gonadotropins,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GA30,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GB,"Ovulation stimulants, synthetic",The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GB01,cyclofenil,NA,NA,0.14,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GB,"Ovulation stimulants, synthetic",The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GB02,clomifene,NA,NA,9,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GB,"Ovulation stimulants, synthetic",The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GB03,epimestrol,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03H,ANTIANDROGENS,G03HA,"Antiandrogens, plain",The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the treatment of hypersexualism.,G03HA01,cyproterone,NA,NA,0.1,0.1,NA,NA,NA,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03H,ANTIANDROGENS,G03HB,Antiandrogens and estrogens,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the treatment of hirsutism or prophylaxis of postmenopausal osteoporosis.,G03HB01,cyproterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03X,OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03XA,Antigonadotropins and similar agents,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs of danazol and gestrinone are based on the treatment of endometriosis.,G03XA01,danazol,NA,NA,0.6,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03X,OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03XA,Antigonadotropins and similar agents,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs of danazol and gestrinone are based on the treatment of endometriosis.,G03XA02,gestrinone,NA,NA,0.7,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03X,OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03XB,Progesterone receptor modulators,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDD for mifepristone (G03XB01) and for the combination package of mifepristone tablet and misoprostol vaginal tablets (G03XB51) is based on the use in termination of pregnancy.The DDD for the combination package is given as amount of mifepristone.,G03XB01,mifepristone,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03X,OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03XB,Progesterone receptor modulators,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDD for mifepristone (G03XB01) and for the combination package of mifepristone tablet and misoprostol vaginal tablets (G03XB51) is based on the use in termination of pregnancy.The DDD for the combination package is given as amount of mifepristone.,G03XB02,ulipristal,NA,NA,5,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03X,OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03XB,Progesterone receptor modulators,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDD for mifepristone (G03XB01) and for the combination package of mifepristone tablet and misoprostol vaginal tablets (G03XB51) is based on the use in termination of pregnancy.The DDD for the combination package is given as amount of mifepristone.,G03XB51,"mifepristone, combinations",Refers to mifepristone,NA,0.2,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03X,OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03XC,Selective estrogen receptor modulators,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval.,G03XC01,raloxifene,NA,NA,60,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03X,OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03XC,Selective estrogen receptor modulators,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval.,G03XC02,bazedoxifene,NA,NA,20,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03X,OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03XC,Selective estrogen receptor modulators,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval.,G03XC03,lasofoxifene,NA,NA,0.5,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03X,OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03XC,Selective estrogen receptor modulators,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval.,G03XC04,ormeloxifene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03X,OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03XC,Selective estrogen receptor modulators,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval.,G03XC05,ospemifene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03X,OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03XX,Other sex hormones and modulators of the genital system,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval.,G03XX01,prasterone,NA,NA,NA,NA,NA,NA,NA,NA,NA,6.5,NA,NA,NA,NA,NA,NA,NA,NA,mg
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BA,Acidifiers,NA,G04BA01,ammonium chloride,NA,NA,8.5,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BA,Acidifiers,NA,G04BA03,calcium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BC,Urinary concrement solvents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD01,emepronium,NA,NA,0.5,75,NA,NA,NA,NA,NA,NA,NA,g,mg,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD02,flavoxate,NA,NA,0.8,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD03,meladrazine,NA,NA,0.45,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD04,oxybutynin,NA,NA,15,NA,NA,NA,NA,3.9,NA,NA,NA,mg,NA,NA,NA,NA,mg,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD05,terodiline,NA,NA,50,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD06,propiverine,NA,NA,30,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD07,tolterodine,NA,NA,4,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD08,solifenacin,NA,NA,5,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD09,trospium,NA,NA,40,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD10,darifenacin,NA,NA,7.5,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD11,fesoterodine,NA,NA,4,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD12,mirabegron,NA,NA,50,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD13,desfesoterodine,NA,NA,3.5,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD14,imidafenacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD15,vibegron,NA,NA,75,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BE,Drugs used in erectile dysfunction,The DDDs are based on single treatment of erectile dysfunction.,G04BE01,alprostadil,NA,NA,NA,20,NA,NA,NA,NA,0.25,NA,NA,NA,mcg,NA,NA,NA,NA,mg,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BE,Drugs used in erectile dysfunction,The DDDs are based on single treatment of erectile dysfunction.,G04BE02,papaverine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BE,Drugs used in erectile dysfunction,The DDDs are based on single treatment of erectile dysfunction.,G04BE03,sildenafil,NA,NA,50,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BE,Drugs used in erectile dysfunction,The DDDs are based on single treatment of erectile dysfunction.,G04BE04,yohimbine,NA,NA,15,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BE,Drugs used in erectile dysfunction,The DDDs are based on single treatment of erectile dysfunction.,G04BE06,moxisylyte,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BE,Drugs used in erectile dysfunction,The DDDs are based on single treatment of erectile dysfunction.,G04BE07,apomorphine,NA,NA,NA,NA,NA,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BE,Drugs used in erectile dysfunction,The DDDs are based on single treatment of erectile dysfunction.,G04BE08,tadalafil,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BE,Drugs used in erectile dysfunction,The DDDs are based on single treatment of erectile dysfunction.,G04BE09,vardenafil,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BE,Drugs used in erectile dysfunction,The DDDs are based on single treatment of erectile dysfunction.,G04BE10,avanafil,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BE,Drugs used in erectile dysfunction,The DDDs are based on single treatment of erectile dysfunction.,G04BE11,udenafil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BE,Drugs used in erectile dysfunction,The DDDs are based on single treatment of erectile dysfunction.,G04BE30,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BE,Drugs used in erectile dysfunction,The DDDs are based on single treatment of erectile dysfunction.,G04BE52,"papaverine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BX,Other urologicals,"The DDD of phenazopyridine is based on analgesic treatment of conditions such as cystitis, prostatitis and urethritis.  The DDD for phenylsalicylate is based on the prophylaxis of urinary tract infections.  The other DDDs are based on the prophylaxis of urinary concrements.",G04BX01,magnesium hydroxide,NA,NA,0.5,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BX,Other urologicals,"The DDD of phenazopyridine is based on analgesic treatment of conditions such as cystitis, prostatitis and urethritis.  The DDD for phenylsalicylate is based on the prophylaxis of urinary tract infections.  The other DDDs are based on the prophylaxis of urinary concrements.",G04BX03,acetohydroxamic acid,NA,NA,0.75,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BX,Other urologicals,"The DDD of phenazopyridine is based on analgesic treatment of conditions such as cystitis, prostatitis and urethritis.  The DDD for phenylsalicylate is based on the prophylaxis of urinary tract infections.  The other DDDs are based on the prophylaxis of urinary concrements.",G04BX06,phenazopyridine,NA,NA,0.6,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BX,Other urologicals,"The DDD of phenazopyridine is based on analgesic treatment of conditions such as cystitis, prostatitis and urethritis.  The DDD for phenylsalicylate is based on the prophylaxis of urinary tract infections.  The other DDDs are based on the prophylaxis of urinary concrements.",G04BX10,succinimide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BX,Other urologicals,"The DDD of phenazopyridine is based on analgesic treatment of conditions such as cystitis, prostatitis and urethritis.  The DDD for phenylsalicylate is based on the prophylaxis of urinary tract infections.  The other DDDs are based on the prophylaxis of urinary concrements.",G04BX11,collagen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BX,Other urologicals,"The DDD of phenazopyridine is based on analgesic treatment of conditions such as cystitis, prostatitis and urethritis.  The DDD for phenylsalicylate is based on the prophylaxis of urinary tract infections.  The other DDDs are based on the prophylaxis of urinary concrements.",G04BX12,phenyl salicylate,NA,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BX,Other urologicals,"The DDD of phenazopyridine is based on analgesic treatment of conditions such as cystitis, prostatitis and urethritis.  The DDD for phenylsalicylate is based on the prophylaxis of urinary tract infections.  The other DDDs are based on the prophylaxis of urinary concrements.",G04BX13,dimethyl sulfoxide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BX,Other urologicals,"The DDD of phenazopyridine is based on analgesic treatment of conditions such as cystitis, prostatitis and urethritis.  The DDD for phenylsalicylate is based on the prophylaxis of urinary tract infections.  The other DDDs are based on the prophylaxis of urinary concrements.",G04BX14,dapoxetine,NA,NA,30,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BX,Other urologicals,"The DDD of phenazopyridine is based on analgesic treatment of conditions such as cystitis, prostatitis and urethritis.  The DDD for phenylsalicylate is based on the prophylaxis of urinary tract infections.  The other DDDs are based on the prophylaxis of urinary concrements.",G04BX15,pentosan polysulfate sodium,NA,NA,0.3,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BX,Other urologicals,"The DDD of phenazopyridine is based on analgesic treatment of conditions such as cystitis, prostatitis and urethritis.  The DDD for phenylsalicylate is based on the prophylaxis of urinary tract infections.  The other DDDs are based on the prophylaxis of urinary concrements.",G04BX16,tiopronin,NA,NA,0.8,NA,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BX,Other urologicals,"The DDD of phenazopyridine is based on analgesic treatment of conditions such as cystitis, prostatitis and urethritis.  The DDD for phenylsalicylate is based on the prophylaxis of urinary tract infections.  The other DDDs are based on the prophylaxis of urinary concrements.",G04BX17,sodium salicylate and methenamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CA,Alpha-adrenoreceptor antagonists,NA,G04CA01,alfuzosin,NA,NA,7.5,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CA,Alpha-adrenoreceptor antagonists,NA,G04CA02,tamsulosin,NA,NA,0.4,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CA,Alpha-adrenoreceptor antagonists,NA,G04CA03,terazosin,NA,NA,5,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CA,Alpha-adrenoreceptor antagonists,NA,G04CA04,silodosin,NA,NA,8,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CA,Alpha-adrenoreceptor antagonists,NA,G04CA51,alfuzosin and finasteride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CA,Alpha-adrenoreceptor antagonists,NA,G04CA52,tamsulosin and dutasteride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CA,Alpha-adrenoreceptor antagonists,NA,G04CA53,tamsulosin and solifenacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CA,Alpha-adrenoreceptor antagonists,NA,G04CA54,tamsulosin and tadalafil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CA,Alpha-adrenoreceptor antagonists,NA,G04CA55,doxazosin and finasteride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CB,Testosterone-5-alpha reductase inhibitors,NA,G04CB01,finasteride,NA,NA,5,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CB,Testosterone-5-alpha reductase inhibitors,NA,G04CB02,dutasteride,NA,NA,0.5,NA,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CB,Testosterone-5-alpha reductase inhibitors,NA,G04CB51,finasteride and tadalafil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CX,Other drugs used in benign prostatic hypertrophy,NA,G04CX01,Prunus africanae cortex,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CX,Other drugs used in benign prostatic hypertrophy,NA,G04CX02,Sabalis serrulatae fructus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CX,Other drugs used in benign prostatic hypertrophy,NA,G04CX03,mepartricin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CX,Other drugs used in benign prostatic hypertrophy,NA,G04CX04,fexapotide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
